CHICAGO, March 18, 2022 /PRNewswire/ -- According to the new market research report "Cancer Biomarkers Market by Type (Protein, Genetic), Cancer (Lung, Breast, Leukemia, Melanoma, Colorectal), Profiling Technology (Omics, Imaging, Immunoassay, Bioinformatics), Application (Diagnostics, R&D, Prognostics), Region - Global Forecast to 2026", published by MarketsandMarkets, the global market is projected to reach USD 28.2 billion by 2026 from USD 12.4 billion in 2021, at a CAGR of 17.7%.
Browse in-depth TOC on "Cancer Biomarkers Market"
229 - Tables
50 - Figures
287 - Pages
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=202
The Growing preference for wireless connectivity among healthcare providers, Increasing incidence of cancer worldwide, increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers are among the other factors. Emerging economies such as India and Japan are providing lucrative opportunities for the players operating in the market.
The protein biomarkers segment accounted for the largest share of the cancer biomarkers market, by biomarker type segment, in 2020
Based on biomarkers type, the market is segmented into protein biomarkers, genetic biomarkers and other cancer biomarkers. The protein biomarkers segment accounted for the largest share of the cancer biomarker market, mainly due to rising technological advancements In the development of cancer biomarkers and increasing R&D on cancer biomarkers.
Lung cancer segment to register the highest growth rate during the forecast period
The cancer biomarker market is segmented into breast cancer, lung cancer, colorectal cancer, prostate cancer, melanoma, leukemia, thyroid cancer, bladder cancer, non-hodgkins lymphoma, kidney cancer and other cancer types based on cancer type. In 2020, the breast cancer segment accounted for the largest share of the cancer biomarkers market. The large share of this segment can mainly be attributed to the increasing incidence of cancer worldwide and increasing use of cancer biomarkers in drug discovery & development.
Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=202
The omics technology accounted for the largest share of the cancer biomarkers market, by profiling technology segment, in 2020
Based on profiling technology, the market has been segmented into omics technologies, imaging technologies, immunoassay, bioinformatics, and cytogenetics. In 2020, the omics technology segment accounted for the largest share of the cancer biomarker market, mainly due to the increasing use of cancer biomarkers in drug discovery & development and increasing R&D on cancer biomarkers.
The diagnostics segment accounted for the largest share of the cancer biomarkers market, by application segment, in 2020
Based on application, the cancer biomarker market has been segmented into diagnostics, research & development, prognostics, risk assessment, and other applications. In 2020, the diagnostics segment accounted for the largest share of the cancer biomarker market, mainly due to the increasing incidence of cancer worldwide and increasing use of cancer biomarkers in drug discovery & development.
Speak to Analyst: https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=202
North America is the largest regional market for cancer biomarkers market
The global cancer biomarker market is segmented into five major regions - North America, Europe, the Asia Pacific, Latin America, and the Middle East & Africa. North America accounted for the largest regional market for market in 2020. The large share of North America in this market can be attributed to the rising technological advancements In the development of cancer biomarkers, increasing incidence of cancer worldwide, and increasing use of cancer biomarkers in drug discovery & development.
The major players operating in this Cancer Biomarkers Market are F. Hoffmann-La Roche Ltd. (Switzerland), Thermo Fisher Scientific, Inc. (US), QIAGEN N.V. (Netherlands),; Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), Abbott Laboratories (US), bioMérieux SA (US), Becton, Dickinson and Company (US), Merck Millipore (US), Agilent Technologies (US), Myriad Genetics, Inc. (US), Sysmex Corporation (Japan), Hologic, Inc. (US), Quest Diagnostics (US), Centogene N.V. (Germany), PerkinElmer, Inc.; (US), Siemens Healthineers (Germany), Exact Sciences (US), R&D Systems, Inc. (US), BioVision, Inc. (US), Olink (Sweden), Asuragen, Inc. (US), Meso Scale Diagnostics, LLC (US), Invivoscribe, Inc. (US), Seegene Technologies, Inc. (South Korea).
Browse Adjacent Markets: Medical Devices Market Research Reports & Consulting
Browse Related Reports:
Cancer Diagnostics Market by Product (Consumables (Anitibodies, Probes), Instruments (Pathology Instruments, Imaging Instruments, Biopsy), Technology (IVD Testing), Application (Breast Cancer, Lung Cancer), End User (Hospitals)- Global Forecasts to 2026
https://www.marketsandmarkets.com/Market-Reports/cancer-diagnostics-market-186559121.html
Biomarkers Market by Product (Consumable, Service), Type (Safety, Efficacy, Validation), Disease (Cancer (Solid & Liquid Biopsy), Neurological), Application (Diagnostics, Drug Discovery & Development, Personalized Medicine) - Global Forecast to 2026
https://www.marketsandmarkets.com/Market-Reports/biomarkers-advanced-technologies-and-global-market-43.html
About MarketsandMarkets
MarketsandMarkets provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets for their painpoints around revenues decisions.
Our 850 fulltime analyst and SMEs at MarketsandMarkets are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.
MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledge Store" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.
Contact:
Mr. Aashish Mehra
MarketsandMarkets INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/oncology-biomarkers.asp
Visit Our Web Site: https://www.marketsandmarkets.com
Content Source: https://www.marketsandmarkets.com/PressReleases/oncology-biomarkers-market.asp
Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg
